Genetron Health has partnered with Siemens Healthineers to enable large-scale application of its S5 platform and lung cancer 8-gene IVD assay in hospitals in China.
The aim is to offer individualised diagnosis and treatment guidance for patients with non-small cell lung cancer (NSCLC). Genetron and Siemens intend to standardise molecular testing for cancer.
Genetron’s lung cancer 8-gene IVD assay is based on the company’s One-Step Seq technology. The test can simultaneously identify multiple mutations and fusions across eight genes, the company said.
Designed to help in the selection of targeted treatment for NSCLC, the assay enables quick and precise molecular typing, guidance on medication and tracking of drug resistance.
When used with Genetron S5, the assay has further benefits, such as detection efficiency, easy usage and a two-day turnaround time.
Genetron said that the assay can be used for independent clinical molecular testing at all levels in hospitals across China.
Genetron Health co-founder and CEO Sizhen Wang said: “We are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.
“We also expect this partnership to help standardise cancer molecular testing in China, and reach more patients in need.”
The Genetron Health portfolio includes molecular profiling tests, screening products to find cancer early and companion diagnostics.
Siemens Healthineers Greater China laboratory diagnostics vice-president Guo Yiming said: “To help Chinese cancer patients access quality care, we are not only introducing cutting-edge testing analysers and reagents to China but are also working with local innovators to offer personalised diagnostics.
“Meanwhile, we expect to push forward precision care in the field of lung cancer, therefore contributing to the vision of a healthy China.”
In June last year, Genetron Health collaborated with Thermo Fisher Scientific to expand precision cancer diagnosis and monitoring in Chinese public hospitals.